Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  MlLXSpVv[3Srb36gRZN{[Xl? NYTmbW9yOC53L{GvNk42KM7:TR?= NHPGcHQ{KGh? NYPKTlhzemWmdXPld{B1cGViYnHzZYwhS0JidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1viSVI3ODl5OEez
T24 BC  NYS2WmFOS2WubDDWbYFjcWyrdImgRZN{[Xl? M1TDS|AvPS9zL{KuOUDPxE1? M1XobFI1KGh? NHjtcJVmdmijbnPld{B{d3KjZnXubYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDk[YNz\WG|ZR?= M3HLNVI3ODl5OEez
T24 BC  M{P4OmFxd3C2b4Ppd{BCe3O|YYm= NUjnOVUzOi53IN88US=> M3zFZ|I1KGh? NEXQUFF{\W6|aYTpfoV{KEKFIHPlcIx{KHSxIIPvdoFn\W6rYj3pcoR2[2WmIHHwc5B1d3SrY9Mg Mo\UNlYxQTd6N{O=
HepG2 MXLGeY5kfGmxbjDBd5NigQ>? MYCyNOKh|ryP NWrRO5l2OjUEoHi= MnvHdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{ NG\GbnkzPTl|NEKzNi=>
U-87 MG  NULlWpZCTnWwY4Tpc44hSXO|YYm= NV7NUFF7OjEEoN88US=> NX;xfGtUOjUEoHi= MljUbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC|dIL1Z5R2emW| MUGyOVk{PDJ|Mh?=
HepG2 M2nMb2Z2dmO2aX;uJGF{e2G7 NI\lXnUzOMLizszN MWq2M|I1KGh? M3Xx[Ylv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? NHO0TlEzPTl|NEKzNi=>
U-87 MG  NVrGb|VpTnWwY4Tpc44hSXO|YYm= NX7jdWp6OjEEoN88US=> MXe2M|I1KGh? M3fTW4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? MUeyOVk{PDJ|Mh?=
HepG2 MnvHSpVv[3Srb36gRZN{[Xl? MlP1NlDDqM7:TR?= MnXSOk8zPCCq NIfxNopl\WO{ZXHz[ZMhVEN|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>? MnvsNlU6OzR{M{K=
U-87 MG  NX\5WodOTnWwY4Tpc44hSXO|YYm= MVqyNOKh|ryP MXe2M|I1KGh? MUHpcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? NUnYV3djOjV7M{SyN|I>
HepG2 NWqwd3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30SYkzOC92MDFOwG0> M1\uXlI1NzR6IHi= NIHWTI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M2jNd|I2QTN2MkOy
U-87 MG  NF7icWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXo[YUzOC92MDFOwG0> M{foZVI1NzR6IHi= MlXHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWmyOVk{PDJ|Mh?=
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjCNE4{NTFyIN88US=> MWKyOE84OiCq NFnxZWFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NH7JN4EzPTZ7N{i5PS=>
H460 M3jXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWN29sOC5|LUGwJO69VQ>? MlHYNlQwPzJiaB?= MkjobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NV;WVGNROjV4OUe4PVk>
A549 MVTBdI9xfG:|aYOgRZN{e2G7 MWexM|Mh|ryP MojFOFghcA>? NInFR3hqdmS3Y3XzJIFxd3C2b4Ppdy=> MkDRNlU3QTd6OUm=
H460 M2\nNGFxd3C2b4Ppd{BCe3O|YYm= MlTQNU8{KM7:TR?= MYG0PEBp MWHpcoR2[2W|IHHwc5B1d3Orcx?= M1L3cVI2Pjl5OEm5
A549 NV;C[I5{TnWwY4Tpc44hSXO|YYm= M374RVMh|ryP Ml;CPEBp MmTvZoxw[2u|IFHLWEBi[3SrdnH0bY9v MYSyOVY6Pzh7OR?=
H460 MXHGeY5kfGmxbjDBd5NigQ>? NF2wb20{KM7:TR?= MmXSPEBp NULlOVlK[myxY3vzJGFMXCCjY4TpeoF1cW:w M1\vOlI2Pjl5OEm5
A549 M1y1emZ2dmO2aX;uJGF{e2G7 Ml\BN{DPxE1? NGTtNVM5KGh? M1r6SYJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= NHTjR|gzPTZ7N{i5PS=>
H460 MYjGeY5kfGmxbjDBd5NigQ>? NVfEeXdjOyEQvF2= NVjyTWhLQCCq NVPP[3hM[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y MUWyOVY6Pzh7OR?=
RMG1 M1fseWNmdGxiVnnhZoltcXS7IFHzd4F6 NVrYN49pOS1|MDFOwG0> M1:ycVczKGh? M{jyXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXKyOVUyQTF2OB?=
RMG2 NHvyVW5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFr2eHoyNTNyIN88US=> M1T5eVczKGh? M1HtfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Ml2zNlU2OTlzNEi=
KOC7C M3nBTWNmdGxiVnnhZoltcXS7IFHzd4F6 NYe1T5pZOS1|MDFOwG0> NIfFUJA4OiCq NXLaXJgy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MXeyOVUyQTF2OB?=
HAC2 NVzTXXZCS2WubDDWbYFjcWyrdImgRZN{[Xl? NXXJZVlNOS1|MDFOwG0> MWm3NkBp Mmjx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml7mNlU2OTlzNEi=
RMG2 Ml3uR4VtdCCYaXHibYxqfHliQYPzZZk> MkjUNU0{OCEQvF2= MXi0PEBp NEHCe29l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M2GzcVI2PTF7MUS4
OVISE MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUTld4g5OS1|MDFOwG0> MXi0PEBp Ml64[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVKyOVUyQTF2OB?=
SKOV3 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn3ONU0{OCEQvF2= NWrWfIZtPDhiaB?= NVvucpdK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MYSyOVUyQTF2OB?=
A2780 M4XJUmNmdGxiVnnhZoltcXS7IFHzd4F6 MlvrNU0{OCEQvF2= Mk\DOFghcA>? NXnxR|hT\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NGrxVJUzPTVzOUG0PC=>
RMG1 MnfuRZBweHSxc3nzJGF{e3OjeR?= Ml\CN|Ah|ryP MYmyOEBp MVzpcoR2[2W|IHHwc5B1d3Orcx?= MnvmNlU2OTlzNEi=
RMG2 NWnETYptSXCxcITvd4l{KEG|c4PhfS=> NH7CVlc{OCEQvF2= NIrZfFMzPCCq Mn;CbY5lfWOnczDhdI9xfG:|aYO= NHzycmIzPTVzOUG0PC=>
HCC1806 NWHYNXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMVExKM7:TR?= NWD2d3FJPDhiaB?= M4W2cWVEPTB;Mj64OQKBkcLz4pEJNE4xPyEQvF2= NFr5OHAzPTJ7M{W3Oi=>
MDA-MB-231  MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUixNppKOC1zMDFOwG0> MkTzOFghcA>? MXnFR|UxRTFwMURihKnDueLCiUCuNFch|ryP MYCyOVI6OzV5Nh?=
GL-1 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;zNE4y6oDVMUCw5qCK|ryP MnfnOFghcA>? M161bWlEPTB;OT65NUDPxE1? NX3CUlZLOjR6OEG1NFg>
CLBL-1 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLVNE4y6oDVMUCw5qCK|ryP M3OxW|Q5KGh? M4XJRWlEPTB;M{OuNEDPxE1? MnH5NlQ5QDF3MEi=
UL-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlHjiJNzMEFihKnPxE1? NV3xOXRuPDhiaB?= Mn76TWM2OD15LkCxJO69VQ>? NVO3VG0xOjR6OEG1NFg>
Ema MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGThOWoxNjIkgKOxNFDjiIoQvF2= MYi0PEBp NUDUPGw{UUN3ME21PE44KM7:TR?= MVeyOFg5OTVyOB?=
PANC-1 M{LScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6NE0zPSEQvF2= M4LGelczKGh? MkXvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVyzVXRTOjR3MUm3OVE>
MIA M1\Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjEbYN{OC1{NTFOwG0> MWS3NkBp M2GweIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFnIWoIzPDVzOUe1NS=>
AsPC-1 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPqbpcxNTJ3IN88US=> M2rZc|czKGh? MlPibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MUeyOFUyQTd3MR?=
PANC-1 MmKySpVv[3Srb36gRZN{[Xl? NF31ZVAxNjVizszN NGnsS5AzPCCq MXLpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> MWeyOFUyQTd3MR?=
MIA M3TIemZ2dmO2aX;uJGF{e2G7 NFXXTpgxNjVizszN MUGyOEBp NELkTJNqdmirYnn0d{BCc3RuIGO2T|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB? MoXENlQ2OTl5NUG=
AsPC-1 NFz5O5JHfW6ldHnvckBCe3OjeR?= NX:yNmRtOC53IN88US=> NHH5W3EzPCCq MVzpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> MkjjNlQ2OTl5NUG=
U87MG MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zWN|AuOjVizszN NYTTc|UxOjRvOU[gbC=> NVu2bYlu\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MoG4NlQxPjV3MkK=
SGC7901  Ml;MSpVv[3Srb36gRZN{[Xl? M1LrU|AvPzVxMUFCpO69VQ>? M1fCN|Q5KGh? NWXPfXFJ\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh M{PtXFI{QTF{MkS2
MGC803  MXXGeY5kfGmxbjDBd5NigQ>? MnzlNE44PS9zMNMg{txO MYW0POKhcA>? NInDfZJl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA> M1XlRlI{QTF{MkS2
TykNu MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID5TIJKSzVyPUOuOUDPxE1? Mn7aNlM5PzdyMUK=
TykNuR MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\DTWM2OD13LkWg{txO NECyfJMzOzh5N{CxNi=>
M41 M1T1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37MfmlEPTB;MkSuO{DPxE1? MWSyN|g4PzBzMh?=
M41R MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznPINKUUN3ME2xPU45KM7:TR?= NXS3cXRZOjN6N{ewNVI>
OVCAR8 M4XsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3OW2tIUUN3ME2zNU4yKM7:TR?= NIToUFUzOzh5N{CxNi=>
HeyA8 NV32UJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC3bZNyUUN3ME2yOE4{KM7:TR?= M16zb|I{QDd5MEGy
A2780CP M{Hse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIniTmdKSzVyPUeuOkDPxE1? M2LRVFI{QDd5MEGy
OVCAR5 NF[4d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZUZJYUUN3ME22Mlch|ryP NXy1O3h3OjN6N{ewNVI>
A2780S MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvHZ2JKSzVyPUG0MlUh|ryP NFHjU|IzOzh5N{CxNi=>
MCAS NIXGblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD1zMj61JO69VQ>? MUCyN|g4PzBzMh?=
NCI-H727 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH\WbHcxNTFyMDFOwG0> NXXUTXN3OjRxN{KgbC=> M1vwdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> Mm\qNlI1QTl2M{e=
GOT1 M3fYSGNmdGxiVnnhZoltcXS7IFHzd4F6 NHTqdlgxNTFyMDFOwG0> NHPRNYUzPC95MjDo M1\CdYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> Mk\rNlI1QTl2M{e=
BON1 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWmwMVExOCEQvF2= M1W0TFI1Nzd{IHi= MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NULxN3ZoOjJ2OUm0N|c>
BON1 Mk[zRZBweHSxc3nzJGF{e3OjeR?= M4HDZVAuOTBizszN NX;WN|JOOjRiaB?= MYXpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NIPDVI4zOjR7OUSzOy=>
BON1 MWHGeY5kfGmxbjDBd5NigQ>? MVK3MlUwOTBizszN MkT0PEBp MmDG[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJRp\SCjboTpMYFxd3C2b4TpZ{Bxem:2ZXnud{BDS0x{IHHu[EBD[2xvWFy= M3O2U|IzPDl7NEO3
Kasumi-1 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVmwMVIxKM7:TR?= MUiyOE81QCCq M{TEUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NF64cYszOjRyN{KyPC=>
HL-60 MkfGR4VtdCCYaXHibYxqfHliQYPzZZk> Mnu0NE0zOCEQvF2= M3zrb|I1NzR6IHi= MYjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NVLO[GkyOjJ2MEeyNlg>
Kasumi-1 MVLBdI9xfG:|aYOgRZN{e2G7 NXrqUotGOTBizszN NX7UcGRmOjRiaB?= MlzSbY5lfWOnczDhdI9xfG:|aYO= M1vCcVIzPDB5MkK4
HL-60 NV;LXoFNSXCxcITvd4l{KEG|c4PhfS=> Mm\wNVAh|ryP M1nWTFI1KGh? MkT6bY5lfWOnczDhdI9xfG:|aYO= MlfqNlI1ODd{Mki=
Kasumi-1 MlPOSpVv[3Srb36gRZN{[Xl? NI\wVIQzNjVxNT:xNEDPxE1? MoTnNlQhcA>? MWHk[YNz\WG|ZYOgRYt1KGGwZDDwMWFsfCCuZY\lcJPDqGSxc3Wt[IVx\W6mZX70cJk> NUPIc45bOjJ2MEeyNlg>
HL-60 NXLzcoMyTnWwY4Tpc44hSXO|YYm= MVOyMlUwPS9zMDFOwG0> M1:2elI1KGh? Mkjv[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 NIjSOlIzOjRyN{KyPC=>
Kasumi-1 M4rieWZ2dmO2aX;uJGF{e2G7 NVfFTWVNOi53L{WvNVAh|ryP NH3kO3czPCCq M1fxUIlv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NF3UWYIzOjRyN{KyPC=>
HL-60 MlXYSpVv[3Srb36gRZN{[Xl? M2rwdVIvPS93L{GwJO69VQ>? MXeyOEBp NX7OblJZcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{XEeVIzPDB5MkK4
K562 MWHGeY5kfGmxbjDBd5NigQ>? M2\4XlIxKM7:TR?= NUOwSVdGPDhiaB?= MnKwbY5lfWOnczDheZRweGijZ4pCpC=> MkfaNlI1ODd{Mki=
OCUT1 M3XkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmwMlEuOyEQvF2= M371SlUh\A>? NYTqc4FOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUW1UIJbOjJyOUCyO|E>
K1 M17HdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWxNE4yNTNizszN NFruOoE2KGR? NV3y[4ZlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3e4OFIzODlyMkex
OCUT1 NYnCb3k4TnWwY4Tpc44hSXO|YYm= MmfWN{DPxG1? M4PCRVI1KGh? M{ThUYNifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V? M1zSU|IzODlyMkex
CaOV3 NX\PNZlbS2WubDDWbYFjcWyrdImgRZN{[Xl? MWWxM|UwOTBizszN M3u3blQ5KGh? NETEenRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYKgZ491emWjdHXkJJdqfGhicHHjcIl1[XinbB?= NX7remF[OjF5N{WwOVQ>
SKOV3 M2\uV2N6fG:2b4jpZ4l1gSCDc4PhfS=> NXj0VGtQPSEQvF2= MkjtOFghcA>? MmPj[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> MnLaNlE4PzVyNUS=
A2780 MnrNR5l1d3SxeHnjbZR6KEG|c3H5 Mnm2OUDPxE1? NETxdYs1QCCq M4PVU4VvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NYC3UnVrOjF5N{WwOVQ>
HT-29  M1XTN2N6fG:2b4jpZ4l1gSCDc4PhfS=> NIXwc3c2KM7:TR?= MUS0PEBp MXflcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NWniTYd5OjF5N{WwOVQ>
A498 NVGwOlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\wU|AuPDBizszN M2r2TVczKGh? NEP2dGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWHPPWtROjF4NESwOVA>
CAKI-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfpfHIxNTRyIN88US=> M33BblczKGh? M1vFVWlEPTC-MUCg{txO NW\1NmRIOjF4NESwOVA>
769-P M2ewc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOwMVQxKM7:TR?= NXTkdYxSPzJiaB?= MoLtTWM2OH53LUGwJO69VQ>? M4H1flIyPjR2MEWw
786-0 NFzvOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzyRplbOC12MDFOwG0> MYq3NkBp NHPnVJhKSzVyfkWg{txO NV\lVW5YOjF4NESwOVA>
786-O MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;yd5oxNTJyIN88US=> M3nZVVczKGh? NYPY[o1TcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUmyNVY1PDB3MB?=
CAKI-1 NF:0foJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHnOFBFOC1{MDFOwG0> MUm3NkBp MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGG3TYIzOTZ2NEC1NC=>
769-P NYLKTpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLINE0zOCEQvF2= MXy3NkBp NHq2bmRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{jPVVIyPjR2MEWw
A498 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLjNE0zOCEQvF2= MWq3NkBp NIS2PJZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXSyNVY1PDB3MB?=
CWR22RV1 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkD1NVAh|ryP MoHzNlQhcA>? M{LveIlv[3KnYYPld{B{\W6|aYTpeol1gSCxZjDoeY1idiCFV2KyNnJXOSClZXzsd{B1dyC{YXTpZZRqd25? Mk[5NlE1QTZ{N{O=
CWR22RV1 M3XaNWFxd3C2b4Ppd{BCe3O|YYm= NYfSe5BOOTBizszN NYTwdnI1OjRiaB?= Ml3P[Y5p[W6lZYOgdoFlcWG2aX;uJIlv\HWlZXSgZZBweHSxc3nz MnHYNlE1QTZ{N{O=
CWR22RV1 NHnnWJBHfW6ldHnvckBCe3OjeR?= MlrkOUDPxE1? MYmyOEBp MYTy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?= NIW3[2gzOTR7NkK3Ny=>
HepG2  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3tO446PS9zMD:yNE81OCEQvF2= M4\jW|I1NzR6L{eyJIg> MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MkfYNlA5PDJ2MkW=
Bel-7402 NIG3UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH2OU8yOC9{MD:0NEDPxE1? NI[5TIQzPC92OD:3NkBp MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NX;TUHJuOjB6NEK0NlU>
HepG2  MV;GeY5kfGmxbjDBd5NigQ>? MVi1M|ExNzJyIN88US=> M4m1flI1KGh? NUDMPGxyemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl MmPZNlA5PDJ2MkW=
Bel-7402 NGLYcHVHfW6ldHnvckBCe3OjeR?= NILCdo42NzFyL{KwJO69VQ>? MoL4NlQhcA>? MYfy[ZN2dHS|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V? NVPIdXhUOjB6NEK0NlU>
HepG2  NEP3d2tCeG:ydH;zbZMhSXO|c3H5 M3XQR|UwOTBxMkCg{txO NYnqNlFCOjRxNEigbC=> M2r2eolv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= M2PGVFIxQDR{NEK1
Bel-7402 NXTqeJNKSXCxcITvd4l{KEG|c4PhfS=> NYju[FNsPS9zMD:yNEDPxE1? Mmf5NlQwPDhiaB?= NHvrcG1qdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl Mn;XNlA5PDJ2MkW=
OAW-42 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfP[IZROC12MDFOwG0> NFHtdlk4OsLiaB?= M3zVRmlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MmfRNlA1ODV{OU[=
PA-1  M1LhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMR|AuPDBizszN MkD3O|LDqGh? M3PyWGlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUewS|d1OjB2MEWyPVY>
SKOV3  M1nYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XrOlAuPDBizszN Mk\RO|LDqGh? MX7JR|UxhjNyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUO5SGV5OjB2MEWyPVY>
A2780 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv6NE0zOCEQvF2= NXHpc|BbPDhxN{KgbC=> NHP5XVJKSzVywrC9xsA{yqEQvH2= NHvwfpIzODRyNUK5Oi=>
A2780cis  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrrNE0zOCEQvF2= NYroO3gzPDhxN{KgbC=> MmDrTWM2OMLiPdMgOuKh|ryv MWmyNFQxPTJ7Nh?=
SKW6.4 NV3xVI97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFbVIuOTEEoN88US=> NHTTOIs1QMLiaB?= MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXuyNFE{ODl4MB?=
MAVER NVHRWpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPiVJpSOi1zMNMg{txO MVW0POKhcA>? MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mn3uNlAyOzB7NkC=
BJAB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\INk0yOMLizszN NEDxUno1QMLiaB?= Mmn2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NYfjTFZjOjBzM{C5OlA>
OCI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wVVIuOTEEoN88US=> NWG4Rm9yPDkEoHi= NGflcFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MorNNlAyOzB7NkC=
MOLM M3zDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;zNk0yOMLizszN M2DLSFQ5yqCq NUP1ZmllcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoG4NlAyOzB7NkC=
HL-60 M1HlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQNZEzNTFywrFOwG0> MUe0POKhcA>? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M4Dkc|IxOTNyOU[w
SKW6.4 NYPTNoNOSXCxcITvd4l{KEG|c4PhfS=> MXuxNOKh|ryP MlTuNlQwPDhiaB?= M4WwT4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= NIj3dGczODF|MEm2NC=>
MAVER M{frUWFxd3C2b4Ppd{BCe3O|YYm= NYTYXI9qOTEEoN88US=> M3nwOFI1NzR6IHi= NFrGbmJqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 M3rrT|IxOTNyOU[w
BJAB MVHBdI9xfG:|aYOgRZN{e2G7 NW\3c4hDOTEEoN88US=> M1fDVFI1NzR6IHi= NGPYcJNqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NWnZU4VKOjBzM{C5OlA>
OCI MYnBdI9xfG:|aYOgRZN{e2G7 Mki1NVDDqM7:TR?= NH;LT4MzPC92ODDo NXjKS2VucW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> MYKyNFE{ODl4MB?=
MOLM M{XiPGFxd3C2b4Ppd{BCe3O|YYm= M2LUR|ExyqEQvF2= NFnHV|AzPC92ODDo MUTpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MWqyNFE{ODl4MB?=
HL-60 M3;NbGFxd3C2b4Ppd{BCe3O|YYm= NFv4Zm8yOMLizszN M{HBR|I1NzR6IHi= NVfIWm9EcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NVPmZotwOjBzM{C5OlA>

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID